National Institutes of Health, a Component of the US Dept. of Health & Human Services

Pontificia Universidad Catòlica De Chile

Pontifica Universidad Catoclica De Chile

Christopher R Dextras

Juan Jose Marugan

Noel Terrence Southall

Xin Hu

Marc Ferrer

Rommy M Von Bernhardi

Silvana Zanlungo

Alejandra Alvarez

Daniel C Talley

Andres E Dulcey

Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as 'c-Abl'). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.

c-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

C-Abl tyrosine kinase inhibitory compound embodiments and methods of making and using the same

Growing community of inventors

Frederick, MD, United States of America

Christopher R Dextras